Abstract: Objective The aim of this study was to investigate the short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C (CHC). Methods 132 patients with genotype 3 infected CHC were admitted to our hospital between October 2017 and May 2019, and 66 patients were treated with peginterferon-2a and ribavirin for 24 weeks, and another 66 patients were treated with ritonavir and danorevir at base of standardized therapy for 12 weeks. All patients were followed-up for 24 weeks. Results At the end of 2 week, 4 week and 12 week treatment, the virological response rates in the combination group were 90.9%, 97.0% and 100.0%, respectively, significantly higher than 66.7%, 75.8% and 81.8% in standardized therapy-treated group (P<0.05); at the end of 24 week of follow-up after treatment, the sustained virological response (SVR) in the combination group was 92.4%, significantly higher than 74.2% in the control group (P<0.05); there were no statistically significant differences in white blood cell counts, platelet counts and hemoglobin levels in the two groups (P>0.05) and there wereno significant differences in the incidences of adverse reactions between the two groups (P>0.05).Conclusion The application of ritonavir and danorevir at base of standardized therapy in the treatment of patients with CHC and genotype 3 infection is efficacious and safe, which warrants further investigation.

Key words: Hepatitis C, Danorevir, Ritonavir, Pegylated interferon α-2a, Ribavirin, Therapy